Basit öğe kaydını göster

dc.contributor.authorMccue, S.
dc.contributor.authorMahr, A.
dc.contributor.authorTakeno, M.
dc.contributor.authorKim, D. Y.
dc.contributor.authorSaadoun, D.
dc.contributor.authorDİRESKENELİ, RAFİ HANER
dc.contributor.authorMelikoglu, M.
dc.contributor.authorCheng, S.
dc.contributor.authorParis, M.
dc.contributor.authorYazici, Y.
dc.contributor.authorChen, M.
dc.contributor.authorHatemi, G.
dc.date.accessioned2021-12-10T11:36:03Z
dc.date.available2021-12-10T11:36:03Z
dc.date.issued2021
dc.identifier.citationHatemi G., Mahr A., Takeno M., Kim D. Y. , Saadoun D., DİRESKENELİ R. H. , Melikoglu M., Cheng S., Mccue S., Paris M., et al., "Apremilast for oral ulcers associated with active Behcet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, cilt.39, sa.5, 2021
dc.identifier.issn0392-856X
dc.identifier.otherav_887c3a22-7af1-4767-a7e7-6863510e585d
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/172224
dc.description.abstractObjective. This study assessed the efficacy and safety of apremilast for the oral ulcers associated with Behcet's syndrome (BS) up to 64 weeks.
dc.language.isoeng
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectİmmünoloji ve Romatoloji
dc.subjectHealth Sciences
dc.subjectRheumatology
dc.subjectROMATOLOJİ
dc.subjectKlinik Tıp
dc.titleApremilast for oral ulcers associated with active Behcet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial
dc.typeMakale
dc.relation.journalCLINICAL AND EXPERIMENTAL RHEUMATOLOGY
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume39
dc.identifier.issue5
dc.contributor.firstauthorID2755337


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster